Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, parallel group treatment, Phase 2 open label study evaluating
cobolimab in combination with dostarlimab and docetaxel in participants with advanced
Nonsmall cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and
chemotherapy.